AstraZeneca Focuses on Rare Diseases for $80 Billion Revenue Push

AstraZeneca is strategically emphasizing rare diseases as a key area for its ambitious $80 billion revenue target, with the chief executive of its subsidiary Alexion noting that rare disease medicine remains a largely untapped market.